Cargando…

Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles

A chemical library comprising 2,354 drug-like compounds was screened using a transcription and replication-competent virus-like particle (trVLP) system implementing the whole Ebola virus (EBOV) life cycle. Dose-dependent inhibition of Ebola trVLP replication was induced by 15 hit compounds, which pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Yi-Seul, Jang, Yejin, Hoenen, Thomas, Shin, Heegwon, Lee, Younghoon, Kim, Meehyein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118351/
https://www.ncbi.nlm.nih.gov/pubmed/31964466
http://dx.doi.org/10.5483/BMBRep.2020.53.3.175
_version_ 1783514545217601536
author Yoon, Yi-Seul
Jang, Yejin
Hoenen, Thomas
Shin, Heegwon
Lee, Younghoon
Kim, Meehyein
author_facet Yoon, Yi-Seul
Jang, Yejin
Hoenen, Thomas
Shin, Heegwon
Lee, Younghoon
Kim, Meehyein
author_sort Yoon, Yi-Seul
collection PubMed
description A chemical library comprising 2,354 drug-like compounds was screened using a transcription and replication-competent virus-like particle (trVLP) system implementing the whole Ebola virus (EBOV) life cycle. Dose-dependent inhibition of Ebola trVLP replication was induced by 15 hit compounds, which primarily target different types of G protein-coupled receptors (GPCRs). Based on the chemical structure, the compounds were divided into three groups, diphenylmethane derivatives, promazine derivatives and chemicals with no conserved skeletons. The third group included sertindole, raloxifene, and ibutamoren showing prominent antiviral effects in cells. They downregulated the expression of viral proteins, including the VP40 matrix protein and the envelope glycoprotein. They also reduced the amount of EBOV-derived tetracistronic minigenome RNA incorporated into progeny trVLPs in the culture supernatant. Particularly, ibutamoren, which is a known agonist of growth hormone secretagogue receptor (GHSR), showed the most promising antiviral activity with a 50% effective concentration of 0.2 μM, a 50% cytotoxic concentration of 42.4 μM, and a selectivity index of 222.8. Here, we suggest a strategy for development of anti-EBOV therapeutics by adopting GHSR agonists as hit compounds.
format Online
Article
Text
id pubmed-7118351
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-71183512020-04-09 Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles Yoon, Yi-Seul Jang, Yejin Hoenen, Thomas Shin, Heegwon Lee, Younghoon Kim, Meehyein BMB Rep Article A chemical library comprising 2,354 drug-like compounds was screened using a transcription and replication-competent virus-like particle (trVLP) system implementing the whole Ebola virus (EBOV) life cycle. Dose-dependent inhibition of Ebola trVLP replication was induced by 15 hit compounds, which primarily target different types of G protein-coupled receptors (GPCRs). Based on the chemical structure, the compounds were divided into three groups, diphenylmethane derivatives, promazine derivatives and chemicals with no conserved skeletons. The third group included sertindole, raloxifene, and ibutamoren showing prominent antiviral effects in cells. They downregulated the expression of viral proteins, including the VP40 matrix protein and the envelope glycoprotein. They also reduced the amount of EBOV-derived tetracistronic minigenome RNA incorporated into progeny trVLPs in the culture supernatant. Particularly, ibutamoren, which is a known agonist of growth hormone secretagogue receptor (GHSR), showed the most promising antiviral activity with a 50% effective concentration of 0.2 μM, a 50% cytotoxic concentration of 42.4 μM, and a selectivity index of 222.8. Here, we suggest a strategy for development of anti-EBOV therapeutics by adopting GHSR agonists as hit compounds. Korean Society for Biochemistry and Molecular Biology 2020-03-31 2020-03-31 /pmc/articles/PMC7118351/ /pubmed/31964466 http://dx.doi.org/10.5483/BMBRep.2020.53.3.175 Text en Copyright © 2020 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Yoon, Yi-Seul
Jang, Yejin
Hoenen, Thomas
Shin, Heegwon
Lee, Younghoon
Kim, Meehyein
Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles
title Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles
title_full Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles
title_fullStr Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles
title_full_unstemmed Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles
title_short Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles
title_sort antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent ebola virus-like particles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118351/
https://www.ncbi.nlm.nih.gov/pubmed/31964466
http://dx.doi.org/10.5483/BMBRep.2020.53.3.175
work_keys_str_mv AT yoonyiseul antiviralactivityofsertindoleraloxifeneandibutamorenagainsttranscriptionandreplicationcompetentebolaviruslikeparticles
AT jangyejin antiviralactivityofsertindoleraloxifeneandibutamorenagainsttranscriptionandreplicationcompetentebolaviruslikeparticles
AT hoenenthomas antiviralactivityofsertindoleraloxifeneandibutamorenagainsttranscriptionandreplicationcompetentebolaviruslikeparticles
AT shinheegwon antiviralactivityofsertindoleraloxifeneandibutamorenagainsttranscriptionandreplicationcompetentebolaviruslikeparticles
AT leeyounghoon antiviralactivityofsertindoleraloxifeneandibutamorenagainsttranscriptionandreplicationcompetentebolaviruslikeparticles
AT kimmeehyein antiviralactivityofsertindoleraloxifeneandibutamorenagainsttranscriptionandreplicationcompetentebolaviruslikeparticles